Anna Steward

Anna Steward

Auto-generated profile, based on publicly available information

Anna Steward

Institute for Stroke and Dementia Research (ISD), University Hospital, LMU, Munich Germany

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
SRSebastian N. Roemer-Cassiano
Sebastian N. Roemer-Cassiano
FWFabian Wagner
Fabian Wagner
LELisa Evangelista
Lisa Evangelista
BRBoris-Stephan Rauchmann
Boris-Stephan Rauchmann
ADAmir Dehsarvi
Amir Dehsarvi
NFNicolai Franzmeier
Nicolai Franzmeier
In Alzheimer’s disease (AD), amyloid-β (Aβ) triggers the aggregation and spreading of tau pathology, which drives neurodegeneration and cognitive decline. However, the pathophysiological link between Aβ and tau remains unclear, which hinders therapeutic efforts to attenuate Aβ-related tau accumulation. Aβ has been found to trigger neuronal hyperactivity and hyperconnectivity, and preclinical research has shown that tau spreads across connected neurons in an activity-dependent manner. Here, we hypothesized that neuronal hyperactivity and hypersynchronicity, resulting in functional connectivity increases, constitute a crucial mechanism by which Aβ facilitates the spreading of tau pathology. By combining Aβ positron emission tomography (PET), resting-state functional magnetic resonance imaging, and longitudinal tau-PET in 69 cognitively normal amyloid-negative controls and 140 amyloid-positive patients covering the AD spectrum, we confirmed that Aβ induces hyperconnectivity of temporal lobe tau epicenters to posterior brain regions that are vulnerable to tau accumulation in AD. This was replicated in an independent sample of 55 controls and 345 individuals with preclinical AD and low cortical tau-PET uptake, suggesting that the emergence of Aβ-related hyperconnectivity precedes neocortical tau spreading . Last, using longitudinal tau-PET and mediation analysis, we confirmed that these Aβ-related connectivity increases in tau epicenters to typical tau-vulnerable brain regions in AD mediated the effect of Aβ on faster tau accumulation, unveiling increased connectivity as a potential causal link between the two AD hallmark pathologies. Together, these findings suggest that Aβ promotes tau spreading by eliciting neuronal hyperconnectivity and that targeting Aβ-related neuronal hyperconnectivity may attenuate tau spreading in AD.

10 January 2025 in EMBO Molecular Medicine
Verified
Journal Article
Open access
DBDavina Biel
Davina Biel
MSMarc Suárez-Calvet
Marc Suárez-Calvet
ADAnna Dewenter
Anna Dewenter
ASAnna Steward
Anna Steward
SRSebastian N Roemer
Sebastian N Roemer
NFNicolai Franzmeier
Nicolai Franzmeier
In Alzheimer’s disease (AD), Aβ triggers p-tau secretion, which drives tau aggregation. Therefore, it is critical to characterize modulators of Aβ-related p-tau increases which may alter AD trajectories. Here, we assessed whether factors known to alter tau levels in AD modulate the association between fibrillar Aβ and secreted p-tau 181 determined in the cerebrospinal fluid (CSF). To assess potentially modulating effects of female sex, younger age, and ApoE4, we included 322 ADNI participants with cross-sectional/longitudinal p-tau 181 . To determine effects of microglial activation on p-tau 181 , we included 454 subjects with cross-sectional CSF sTREM2. Running ANCOVAs for nominal and linear regressions for metric variables, we found that women had higher Aβ-related p-tau 181 levels. Higher sTREM2 was associated with elevated p-tau 181 , with stronger associations in women. Similarly, ApoE4 was related to higher p-tau 181 levels and faster p-tau 181 increases, with stronger effects in female ApoE4 carriers. Our results show that sex alone modulates the Aβ to p-tau axis, where women show higher Aβ-dependent p-tau secretion, potentially driven by elevated sTREM2-related microglial activation and stronger effects of ApoE4 carriership in women.

25 December 2023 in Alzheimer's & Dementia
Verified
Journal Article
Open access
FWFabian Wanger
Fabian Wanger
ASAnna Steward
Anna Steward
DBDavina Biel
Davina Biel
ADAnna Dewenter
Anna Dewenter
SRSebastian Niclas Roemer
Sebastian Niclas Roemer
NFNicolai Franzmeier
Nicolai Franzmeier
Background: In Alzheimer’s disease (AD), Amyloid‐beta deposition (Ab) is associated with tau spreading from epicenters to connected regions. Yet, Ab and tau accumulate in strikingly different patterns, and it is unclear how Abdrives tau spreading. We envision two mechanisms, i.e. i) that cortical Ab exerts remote effects and “pulls” tau out of connected epicenters or ii) that tau is pushed out of epicenters, once Ab has reached the tau epicenters (Fig.1A). We tested both mechanisms in AD spectrum patients and determined the predominant mechanism by which Ab drives tau spreading.Methods: We included 313 ADNI participants (n = 110 CN Ab‐, n = 98 CN‐Ab+, n = 70 MCI Ab+, n = 35 Dementia Ab+), with baseline amyloid‐ and longitudinal tau‐PET, based on which we calculated tau‐PET rates of change (ROC) for 200 cortical ROIs (Schaefer‐atlas; Fig.2). Using the same atlas, a resting‐state fMRI‐connectivity template was obtained in 42 healthy controls. For each subject, we determined tau epicenters as 5% of ROIs with highest baseline tau‐PET and assessed epicenter connectivity. Using ROI‐wise regression, we tested whether faster tau‐PET increase was explained by the simultaneous occurrence of i) higher tau‐PET in the epicenter, ii) stronger connectivity to the tau epicenter and iii) higher Ab in the target region (i.e. pull‐effect) or the tau epicenter (i.e. push‐effect). Lastly, we assessed ROI‐wise main effects of local Ab vs. Ab in the tau epicenter on tau‐PET changes, to determine which mechanism predominates.Results: Higher tau and Ab in the epicenter explained faster tau‐PET increase in connected temporo‐parietal and frontal regions (Ab‐push‐effect, Fig.1B). In contrast, Ab‐pull‐effects were found also for late‐Braak regions (Fig.1C). Congruently, we found that Ab push effects dominated over Ab‐pull effects in temporo‐parietal brain regions, whereas Ab‐pull effects dominated in late‐Braak regions (Fig.1D‐F). Lastly, patients in which Ab and tau converged locally showed fastest subsequent tau accumulation (Fig.3).Conclusion: Ab exerts local and remote effects on tau spreading, yet local convergence of Ab and tau in the epicenter may predominantly drive tau spreading. Thus, local convergence of Ab and tau is a key event in AD that gives rise to accelerated tau spreading, previously referred to as cataustrophy.

25 December 2023 in Alzheimer's & Dementia
Verified
Journal Article
Open access
ASAnna Steward
Anna Steward
DBDavina Biel
Davina Biel
ADAnna Dewenter
Anna Dewenter
SRSebastian Niclas Roemer
Sebastian Niclas Roemer
FWFabian Wanger
Fabian Wanger
NFNicolai Franzmeier
Nicolai Franzmeier
Background: Targeting amyloid (Aß) may show highest clinical efficacy when preventing downstream tau spreading and subsequent neurodegeneration. Thus, it’s critical to establish Aß‐PET thresholds at which tau spreading is triggered, which may depend on ApoE4, i.e. a key genetic risk factor for Aß, tau and cognitive decline. Yet, ApoE4’s impact on Aß‐related tau spreading is unclear, which may bias intervention studies. Thus, we assessed whether ApoE4‐carriage facilitates Aß‐associated tau spreading and determined thresholds at which Aß‐related tau trajectories diverge between ApoE4‐carriers vs. non‐carriers. Lastly, we ran simulated trials using tau‐PET endpoints to test whether including ApoE4‐carriers increases the sensitivity to detect treatment effects at lower Aß‐levels.Method: We included non‐demented ADNI subjects (n = 237), and a replication sample (18F‐AV‐1451‐A05 trial, n = 130). We combined ApoE4‐status, amyloid‐PET and longitudinal flortaucipir tau‐PET alongside resting‐state fMRI‐connectivity templates from n = 42 Aß‐ controls to assess connectivity‐based tau spreading (subject‐specific tau epicentre connectivity ranked regions i.e. Q1‐Q4) together with tau accumulation in Braak‐stage specific regions. We used i) mediation models to test whether ApoE4 effects on Braak‐stage specific tau accumulation were mediated by centiloid and ii) linear models to determine the centiloid by ApoE4 interaction on tau accumulation in Q1‐Q4 and Braak‐stage regions and iii) determined confidence interval‐based cut‐points of ApoE4‐related divergence in tau trajectories. Lastly, we estimated ApoE4‐stratified sample sizes to detect simulated treatments effects on tau accumulation across increasing centiloid windows.Result: Using bootstrapped mediation we found that centiloid mediated faster ApoE4‐related tau‐PET increase in early Braak‐stage regions (ADNI/A05, BraakIII: B = 0.19/0.33, p<0.001/<0.001), and that ApoE4 facilitates Aß‐related tau spreading (ApoE4*centiloid interaction on tau‐PET increase) in early Braak‐stage and connectivity‐based ROIs. We identified centiloid cut‐points (∼10‐15) where Aß‐related tau accumulation rates diverged between ApoE4 carriers vs. non‐carriers through Braak and connectivity stages (Fig.1), which replicated across samples. Lastly, focusing on ApoE4‐carriers exclusively in simulated clinical trials increased the sensitivity for detecting treatment effects on tau accumulation at lower centiloid levels (Fig.2).Conclusion: ApoE4 is related to earlier Aß‐related tau accumulation, which may drive faster ApoE4‐related disease progression. Our results are relevant for clinical trial design, illustrating that ApoE4‐carriers may require earlier anti‐Aß intervention to attenuate downstream tau spreading.

24 December 2023 in Alzheimer's & Dementia
Verified
Journal Article
Open access
ASAnna Steward
Anna Steward
DBDavina Biel
Davina Biel
ADAnna Dewenter
Anna Dewenter
SRSebastian Niclas Roemer
Sebastian Niclas Roemer
FWFabian Wanger
Fabian Wanger
NFNicolai Franzmeier
Nicolai Franzmeier
Background: Targeting amyloid (Aß) may show highest clinical efficacy when preventing downstream tau spreading and subsequent neurodegeneration. Thus, it’s critical to establish Aß‐PET thresholds at which tau spreading is triggered, which may depend on ApoE4, i.e. a key genetic risk factor for Aß, tau and cognitive decline. Yet, ApoE4’s impact on Aß‐related tau spreading is unclear, which may bias intervention studies. Thus, we assessed whether ApoE4‐carriage facilitates Aß‐associated tau spreading and determined thresholds at which Aß‐related tau trajectories diverge between ApoE4‐carriers vs. non‐carriers. Lastly, we ran simulated trials using tau‐PET endpoints to test whether including ApoE4‐carriers increases the sensitivity to detect treatment effects at lower Aß‐levels.Method: We included non‐demented ADNI subjects (n = 237), and a replication sample (18F‐AV‐1451‐A05 trial, n = 130). We combined ApoE4‐status, amyloid‐PET and longitudinal flortaucipir tau‐PET alongside resting‐state fMRI‐connectivity templates from n = 42 Aß‐ controls to assess connectivity‐based tau spreading (subject‐specific tau epicentre connectivity ranked regions i.e. Q1‐Q4) together with tau accumulation in Braak‐stage specific regions. We used i) mediation models to test whether ApoE4 effects on Braak‐stage specific tau accumulation were mediated by centiloid and ii) linear models to determine the centiloid by ApoE4 interaction on tau accumulation in Q1‐Q4 and Braak‐stage regions and iii) determined confidence interval‐based cut‐points of ApoE4‐related divergence in tau trajectories. Lastly, we estimated ApoE4‐stratified sample sizes to detect simulated treatments effects on tau accumulation across increasing centiloid windows.Result: Using bootstrapped mediation we found that centiloid mediated faster ApoE4‐related tau‐PET increase in early Braak‐stage regions (ADNI/A05, BraakIII: B = 0.19/0.33, p<0.001/<0.001), and that ApoE4 facilitates Aß‐related tau spreading (ApoE4*centiloid interaction on tau‐PET increase) in early Braak‐stage and connectivity‐based ROIs. We identified centiloid cut‐points (∼10‐15) where Aß‐related tau accumulation rates diverged between ApoE4 carriers vs. non‐carriers through Braak and connectivity stages (Fig.1), which replicated across samples. Lastly, focusing on ApoE4‐carriers exclusively in simulated clinical trials increased the sensitivity for detecting treatment effects on tau accumulation at lower centiloid levels (Fig.2).Conclusion: ApoE4 is related to earlier Aß‐related tau accumulation, which may drive faster ApoE4‐related disease progression. Our results are relevant for clinical trial design, illustrating that ApoE4‐carriers may require earlier anti‐Aß intervention to attenuate downstream tau spreading.

24 December 2023 in Alzheimer's & Dementia
Verified
Journal Article
Open access
ADAnna Dewenter
Anna Dewenter
ASAnna Steward
Anna Steward
ADAmir Dehsarvi
Amir Dehsarvi
DBDavina Biel
Davina Biel
SRSebastian Niclas Roemer
Sebastian Niclas Roemer
NFNicolai Franzmeier
Nicolai Franzmeier
Background: Recent post‐mortem studies suggest that cerebrovascular disease contributes to Alzheimer’s disease (AD) pathophysiology and clinical progression. In particular, cerebral amyloid angiopathy is highly common in AD and has been linked to faster cognitive decline. Yet, in‐vivo evidence on the contribution of cerebrovascular disease to pathobiological and/or clinical AD progression is rare. Thus, we assessed in‐vivo, whether i) higher cerebrovascular burden is associated with accelerated progression of primary AD pathology and ii) whether cerebrovascular burden synergistically accelerates AD‐related cognitive decline.Method: We included n = 256 participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) across the AD spectrum with longitudinal 18F‐flortaucipir tau‐PET (follow‐up∼2.30±1.32 years), 18F‐florbetapir or 18F‐florbetaben Aß‐PET transformed to centiloid (A7: n = 85 Cognitively normal (CN); Aß+: n = 83 CN, n = 57 Mild Cognitive Impairment, n = 31 Dementia). We focused on global white matter hyperintensity (WMH) volume adjusted to intracranial volume and microhemorrhage (MCH) count as well‐established cerebrovascular disease markers. Cognition was probed through the AD Assessment Scale Cognition 13‐item scale (ADAS‐13). Subject‐specific annual changes in tau‐PET and cognition were calculated via linear mixed models, including random slope and intercept. To enhance reproducibility of our findings, statistical analyses were pre‐specified at AsPredicted.org. All statistical models were controlled for age, sex and APOE.Result: Using linear regression, we found no main effect of cerebrovascular disease markers on baseline amyloid‐PET or tau‐PET (ps>0.05). Further, higher cerebrovascular burden was not associated with faster Aß‐related tau‐PET SUVR increase (Fig. 1A+B). In contrast, higher cerebrovascular burden was associated with accelerated cognitive decline. Specifically, interaction models revealed that a higher MCH count was associated with faster cognitive decline at higher tau levels (Fig. 1C), while higher white matter hyperintensity burden was associated with faster cognitive decline at lower tau levels (Fig. 1D).Conclusion: We found no effect of cerebrovascular disease on primary AD pathology. In contrast, cerebrovascular disease was linked to accelerated tau‐associated cognitive decline. This suggests that cerebrovascular disease may not modulate pathobiological AD trajectories but rather add synergistically to AD symptom severity. This has important therapeutic implications, as treating cerebrovascular disease in addition to primary AD pathology (e.g. amyloid) may yield largest clinical efficacy.